RECRUITING

Refinements of Functional Communication Training

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Although treatments for problem behavior, like functional communication training (FCT), can be highly effective in the clinic, changes in the way the FCT is implemented (e.g., when transferring treatment to the home, when teachers implement treatment with poor fidelity) can result in treatment relapse. The goal of this study is to evaluate whether using treatment signals and gradually introducing materials from natural contexts can help mitigate treatment relapse during context changes and poor treatment-integrity scenarios.

Official Title

Stimulus Control Refinements of Functional Communication Training

Quick Facts

Study Start:2021-05-03
Study Completion:2025-12-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT04045600

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:3 Years to 17 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:CHILD
Inclusion CriteriaExclusion Criteria
  1. * Boys and girls from ages 3 to 17
  2. * Destructive behavior that occurs at least 10 times a day despite previous treatment
  3. * Destructive behavior reinforced by social consequences like attention (FCT is not appropriate for automatically reinforced destructive behavior)
  4. * On a stable psychoactive drug regimen for at least 10 half-lives per drug or drug free
  5. * Stable educational plan and placement with no anticipated changes during the child's treatment
  1. * Patients who do not meet the inclusion criteria
  2. * Patients currently receiving 15 or more hours per week of treatment for their destructive behavior
  3. * DSM-5 diagnosis of Rett syndrome or other degenerative conditions (e.g., inborn error of metabolism)
  4. * A comorbid health condition or major mental disorder that would interfere with study participation
  5. * Occurrence of SIB during study assessments that presents a risk of serious or permanent harm (e.g., detached retinas) based on our routine clinical-risk assessment
  6. * Patients requiring drug-treatment changes, but the experimenters will invite these patients to participate if they meet inclusion criteria after drug regimen is stable.

Contacts and Locations

Study Contact

Wayne W Fisher, PhD
CONTACT
8488008503
wayne.fisher@rutgers.edu
Serena Claiborne
CONTACT
8488008504
SClaiborne@childrens-specialized.org

Principal Investigator

Wayne W Fisher, PhD
PRINCIPAL_INVESTIGATOR
Rutgers, The State University of New Jersey

Study Locations (Sites)

Children's Specialized Hospital - Rutgers University Center for Autism Research, Education, and Services
Somerset, New Jersey, 00873
United States

Collaborators and Investigators

Sponsor: Rutgers, The State University of New Jersey

  • Wayne W Fisher, PhD, PRINCIPAL_INVESTIGATOR, Rutgers, The State University of New Jersey

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2021-05-03
Study Completion Date2025-12-31

Study Record Updates

Study Start Date2021-05-03
Study Completion Date2025-12-31

Terms related to this study

Additional Relevant MeSH Terms

  • Aggression
  • Self-injurious Behavior